Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term modulation. Found 13 abstracts

Chen XM, Cvetkovic D, Ma CM, Chen LL. Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance. Medical Physics. 2012 May;39(5):2780-6.
van Vlerken LE, Duan ZF, Little SR, Seiden MV, Amiji MM. Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems. Aaps Journal. 2010 Jun;12(2):171-80.   PMCID: PMC2844507 [Available on 2011/2/9]
Lewis-Wambi JS, Swaby R, Kim H, Jordan VC. Potential of L-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2009 Mar;114(1-2):33-9.   PMCID: PMC28689080
Liu SX, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. BIOLOGICAL CHEMISTRY. 2006 Sep;387(9):1209-13.
Chen XL, Jhee KH, Kruger WD. Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. Journal of Biological Chemistry. 2004 Dec 10;279(50):52082-6.
Ho DH, Covington W, Brown N, Lin SN, Pazdur R, Huo YY, Creaven PJ, Rustum YM, Meropol NJ, Lassere Y, Kuritani J, Hayakawa T. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemotherapy and Pharmacology. 2000 Nov;46(5):351-6.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Laing NM, Belinsky MG, Kruh GD, Bell DW, Boyd JT, Barone L, Testa JR, Tew KD. Amplification of the ATP-Binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Research. 1998 Apr;58(7):1332-7.
Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. European Journal of Cancer. 1998 Sep;34(10):1509-13.
Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 1997 Sep;15(9):3156-63.
Schultz M, Dutta S, Tew KD. Inhibitors of glutathione S-transferases as therapeutic agents. Advanced Drug Delivery Reviews. 1997 Jul 07;26(2-3):91-104.
Johnson SW, Shen DW, Pastan I, Gottesman MM, Hamilton TC. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and - resistant human hepatoma cell lines. Experimental Cell Research. 1996 Jul 10;226(1):133-9.
Devries TJ, Kitson JL, Silvers WK, Mintz B. Expression of Plasminogen Activators and Plasminogen-Activator Inhibitors in Cutaneous Melanomas of Transgenic Melanoma- Susceptible Mice. Cancer Research. 1995 Oct 15;55(20):4681-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term modulation

modulation 5-fluorouracil trial carcinoma tegafur gene colorectal-carcinoma doxorubicin resistance phase-i leucovorin fluorouracil proteins liver estrogenicity drug-resistance drug-delivery liposomes urokinase-type sequence-independent amplification capecitabine uracil AhR alkylating-agents Low dose estrogen therapy Antihormone resistance-Apoptosis-Breast cancer-L-Buthionine sulfoximine-Glutathione chromatography targeted delivery malignant skin melanoma estrogen deprivation cytotoxicity combination therapy mechanisms colorectal cancer responsiveness cells nitrogen mustard-resistant human colon transactivation chemotherapy TER 199 selective AhR modulators bisphenol-a TER 286 human-tissues binding mitomycin-c therapy site-directed mutagenesis angiogenesis transcription alzheimers-disease mutations cis-diamminedichloroplatinum(ii) accumulation tamoxifen UFT oral chemotherapy ethacrynic-acid l1210 leukemia-cells induction phase-ii clinical-trial melphalan breast-cancer glucosylceramide alpha-class ph-sensitive system region plasma homocysteine cyto-toxicity 3 2-7-8-tetrachlorodibenzo-para-dioxin microtubule assembly invitro human ovarian-cancer intracellular ceramide modulation n-acetylcysteine multidrug-resistance invivo Biochemistry & Molecular Biology disruption accumulation cancer Ftorafur(tegafur) cyclic-amp poly(beta-amino ester) nanoparticles temporal-controlled polymeric nanoparticle delivery infusion fluorouracil migrating endothelial-cells mechanism brain tubulin drug resistance cross-talk solid tumors ethynyluracil tumor-cells ethacrynic continuous-infusion 5-fluorouracil acid alkylating agents ovarian-cancer invasion etoposide 5-ethynyluracil 776c85 5-FU sensitive cell-lines p- multidrug repair estradiol model inhibition anti-tumor activity S-1 vinblastine degradation breast-cancer-cells pharmacology adriamycin uft dihydropyrimidine dehydrogenase carcinoma cells toxicity mouse brain-tissue adjuvant prostate cancer 1993 en ll-ultrasound in medicine and biology-v19-p67 amphotericin-b glutathione depletion glycoprotein antigen prednisone quality focused ultrasound doxorubicin-HIFU-prostate cancer hydrophobic drugs antimitotic drug hydrogen-sulfide aromatic-hydrocarbons
Last updated on Friday, August 07, 2020